How To Fund Your MedTech: Non-Dilutive Funding Options. A HealthTech Hub Masterclass.

How To Fund Your MedTech: Non-Dilutive Funding Options.

We've assembled a stellar lineup of experts to discuss the funding landscape in Healthtech & Medical Devices. 
Learn how your value proposition determines the optimal timing and strategies for maximising your chances of success.

What You Will Learn:

• How to build a staged funding strategy and/or comprehensive business plan
• What are funding and philanthropic bodies looking for?
• How to build an investment strategy combining different sources of funding
• Dilutive vs non-dilutive - which is right for me?
• When to pivot or change my capital raising strategy?
• How to avoid potential pitfalls in non-dilutive funding strategy?
• What are the risks in non-dilutive funding?
• How to secure continuous support from funders 
• Key considerations in professional grant writing

Agenda:

11:30am: Registration + light lunch networking

12:10pm: Masterclass
1:25pm: Q&A & Panel Discussion
1:50pm: What's next
2:00pm: Event conclude

Meet the Experts: To Be Announced.

-----------

Don't miss this opportunity to gain valuable insights from industry experts and network with fellow health tech innovators.

Register now to secure your spot in this must-attend masterclass for health tech entrepreneurs looking to amplify their presence in the market!

Cicada Innovations is proud to be collaborating with the Westmead Health & Innovation District, Australia’s fastest-growing health and innovation precinct, for this commercialisation masterclass series. These masterclasses are to help bridge the gap between research and commercialisation.

Find out more about the Cicada HealthTech Hub 

The Cicada HealthTech Hub is proudly supported by NSW Government and is part of the Westmead’s Health & Innovation District. The district includes 4 major hospitals, 4 world-leading medical research institutes, 2 university campuses and the largest research-intensive pathology service in NSW. By 2036, the number of full-time staff will increase to more than 50,000 and the number of students will expand to more than 10,000. Among the first projects for development is a viral vector advanced manufacturing facility to provide ground-breaking trial therapies for infections, cancer and genetic diseases.